omalizumab (Xolair)

09/01/2014 - "In these studies, omalizumab reduced exacerbations, asthma symptoms, inhaled corticosteroid and rescue medication use, and improved quality of life relative to placebo or best standard of care. "
11/01/2005 - "Responder analysis shows that omalizumab provides the greatest benefit in patients with more severe asthma, and this has been confirmed by recent studies establishing the efficacy of omalizumab in patients whose asthma is poorly controlled despite receiving the best standard care in medication. "
03/01/2015 - "Omalizumab improved most clinical parameters of Mexican patients with difficult-to-control asthma. "
04/01/2011 - "Omalizumab has been shown to be highly effective in treating children and adults with moderate to severe allergic asthma. "
11/01/2007 - "Omalizumab is not cost-effective for most patients with severe asthma. "

02/01/2014 - "Omalizumab is effective in most subsets of chronic urticaria sufferers who do not respond to other treatments but its high cost represents a limitation to its widespread use. "
08/01/2012 - "Two multicenter, randomized, placebo-controlled trials in chronic spontaneous urticaria have shown excellent efficacy of omalizumab. "
10/01/2010 - "Because of a poor response and dramatic escalation of symptoms, we initiated therapy with omalizumab resulting in the complete remission of the chronic urticaria after two weeks."
01/01/2014 - "In several clinical trials published between 2011 and 2013, omalizumab significantly reduced or eliminated symptoms of chronic urticaria. "
11/01/2012 - "During omalizumab treatment, the urticaria activity score declined significantly (12.11±1.97 to 2.7±4.23; P=0.001) and the CU-quality of life score improved significantly (34.65±13.58 to 60.88±11.11; P=0.004). "

05/01/2014 - "Studies on the efficacy of omalizumab in allergic rhinitis that assessed clinical outcomes were selected. "
03/01/2006 - "This review summarizes two investigative studies examining the safety and efficacy of the combination of omalizumab + allergen SIT for the treatment of allergic rhinitis. "
02/01/2002 - "In patients with allergic rhinitis, omalizumab reduced the severity of symptoms and rescue antihistamine usage versus placebo. "
12/01/2015 - "Interesting results also arise from studies in which omalizumab was administered in patients with allergic rhinitis. "
05/01/2014 - "Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials."

01/01/2001 - "* Omalizumab significantly improved health-related quality-of-life and nasal symptoms in patients with seasonal allergic rhinitis. "
12/01/2006 - "Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis."
12/01/2003 - "In a randomized, double-blind, placebo-controlled clinical trial 24 subjects (16 receiving omalizumab and 8 receiving placebo) with seasonal allergic rhinitis received the study drug on days 0 and 28. "
10/15/2001 - "A Phase II dose-ranging study demonstrated that the optimum efficacious dose of omalizumab for the treatment of seasonal allergic rhinitis is 300 mg administered subcutaneously. "
01/01/2009 - "Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated."

06/01/2010 - "We present 3 patients with severe, treatment resistant atopic dermatitis whose cutaneous symptoms significantly improved by treatment with omalizumab."
09/01/2012 - "Omalizumab is a well-tolerated and safe drug that can be useful for the treatment of severe atopic dermatitis refractory to other systemic therapies. "
09/01/2008 - "Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study."
09/01/2012 - "A number of studies have been published on the usefulness of omalizumab in the treatment of atopic dermatitis, and the results have been variable. "
11/01/2014 - "Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial."